Week 4 - Pharmacogenetics Flashcards

1
Q

Pharmacogenetics is the branch of pharmacology that involves identifying _______ ______ leading to ____-______ differences in drug response.

A

genetics variations, inter-individual

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Pharmacogenetics refers to _______ (_____ gene) variants that affect a patient‘s ______ to a particular drug

A

monogenetic, single, response

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Pharmacogenomics refers to the entire spectrum of _____ that are involved in determining a patient‘s _______ to a particular drug.

A

genes, response

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

The goal of the drug therapy is to produce a specific _________ _____ in a patient without producing ______ effects.

A

pharmacologic effect, adverse

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What are the main causes of variability to drug response?

A
  • Age
  • Health or disease status
  • Species
  • Gender
  • Breed
  • Drug interactions (other drugs administered simultaneously)
  • The patient‘s genome! (mutations, deletions, polymorphisms)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

_________ and _____ of drugs is different from one individual to another

A

Effectivity, safety

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Why is pharmacogenetics important?
Individual variations to drug therapy can cause
• Lack of therapeutic ______
• Unexpected ______ effects (______)

A

efficacy, harmful, Toxicity

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q
A
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Pharmacogenetics can alter both drug _______ and the likelihood of _______.

A

efficacy, toxicity

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

____________ in drug receptors, drug _______ and in drug metabolizing ______.

A

Polymorphisms, transporters, enzymes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Pharmacogenetics combines the areas of pharmacokinetics, how genetic differences
alter ______, and pharmacodynamics, how _____ alter ______ and _____ molecules.

A

ADME, genes, receptors, signal

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Individualization of drug therapy has two important clinical implications:
• It can help predict those patients at _____ risk for developing drug ______. In those cases, a ______
drug dose or an ________ drug should be use.
• It can help identify those patients that are most likely to ______ from a particular drug.

A

high, toxicity, lower, alternative, benefit

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

The human genome contains approximately ___ _______ nucleotide bases, representing roughly ________ ______.

A

3 billion, 30,000 genes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

A gene is the DNA sequence containing a series of _____ (_____ _________ nucleotide bases form a specific codon) that specify a particular _____.

A

codons, three, consecutive, protein

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

A mutation alters the ________ of nucleotide bases in a DNA molecule. This in turn alters _________ _____, creating a different ____.

A

sequence, transcribed RNA, codon

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

A silent mutation results in a _____ change that creates a codon for the _____ amino acid. There is ____ ______ in protein ______ or _____.

A

base, same, no change, structure, function

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

A mutation results in a different _____ _____, or the creation of a ____ ____, the change in protein ______ and _______ can be deleterious.

A

amino acid, stop codon, structure, function

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

At each gene locus, an individual carriers ____ _____, one from each _____.

A

two alleles, parent

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

If an individual has two identical alleles, that individual is said to have a ?

A

homozygous genotype

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

If an individual has two different alleles, that individual is said to have a ?

A

heterozygous genotype

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

The phenotype of each individual with regard to a specific gene is the _______, _______ manifestation of a given genotype. That outward ______ manifestation might be something immediately _______, or it may not be apparent until a particular _____ is administered to that individual.

A

outward, physical, physical, obvious, drug

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Polymorphisms are _________ in a given gene may be present ______ in a population, or in relatively ______ numbers in a population.

A

variations, rarely, large

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

Polymorphisms are defined as ______ _____ occurring at a frequency of % or _____ in the population (species of interest).

A

genetic variations, 1, greater

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
24
Q

In humans, many of the genes encoding cytochrome P450 enzymes are _______, whereas some inherited human diseases such as cystic fibrosis are caused by ____ _______ occurring in _____ than __% of the population.

A

polymorphic, rare, mutations, less, 1

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
25
For some diseases, identification of a specific mutation may be used to provide ______ \_\_\_\_\_\_ approaches for the patient and in the case of veterinary patients, guide ________ decisions, too.
specific treatment, breeding
26
Some relevant genetic defects in veterinary medicine affecting drug therapy:
* MDR1 defect * Cytochrome P450 enzymes * Glucuronyltransferase * N-Acetyltransferase
27
MDR1 defect in dogs are caused by a ________ (\_\_ bp) in the \_\_\_\_\_-\_\_\_\_\_ ________ gene (MDR1-gene, \_\_\_\_\_\_- gene) which leads to the formation of _______ protein (?).
deletion, 4, multi-drug resistance, ABCB1, shortened, P-glycoprotein
28
The MDR1 defect in dogs was originally described in ?
the Collie (ivermectin sensitive) and related breeds (Shetland Sheepdog, Australian Shepherd, Border Collie, mixed breeds, etc)
29
P-glycoprotein is a _______ protein that was first described in _____ \_\_\_\_\_\_\_ ____ cell lines. These tumor cells were ____ \_\_\_\_\_\_ to various _______ agents.
transmembrane, highly resistant tumor, cross resistant, anticancer
30
P-glycoprotein is an \_\_\_\_-dependent _____ which works as an _____ transporter that pumps drugs _____ of the cell and is a functional component of several body \_\_\_\_\_\_, such as?
ATP, carrier, efflux, out, barriers, ## Footnote * Intestine * Kidney * Brain (blood-brain barrier) * Testicles (blood-testis barrier) * Placenta * Liver (bile canaliculi)
31
The MDR1 defect in dogs Expression of P-gp in dogs and relevance in drug disposition
32
MDR1 defect protein; green circles = all drug going to brain; left side of image only some drug entering brain
33
Dogs homozygous for the normal MDR1 allele, can receive ______ µg/Kg of ivermectin as a _____ dose ______ signs of toxicity.
2000, single, without
34
Dogs homozygous for the _______ experience ______ \_\_\_\_\_\_ effects after a _____ dose of ___ µg/Kg ivermectin.
deletion, adverse neurological, single, 120
35
MDR1 +/+ dog Drug can not enter
36
MDR1 -/- dog Drugs able to enter brain
37
\_\_\_\_\_\_ _______ was used to image the head of two Collies after IV injection of P-gp substrate 99mTc-MIBI.
Nuclear scintigraphy,
38
With defective P-gp function has accumulated the P-gp substrate within brain tissue
39
MDR1 +/+ dog Images of the abdomen of dogs positioned in ventral recumbency on a gamma camera. Images were acquired 2 hours after IV injection of 99mTC-MIBI to an MDR1 WT/WT dog and to an MDR1 mut/mut dog Intense uptake of 99mTC-MIBI in the gallbladder (arrowhead) is present in MDR1 normal dog. A void of activity in the location of the gallbladder (arrow) is present in MDR1 mutant dog Most substrate is concentrated in the gallbladder.
40
MDR1 -/- dog Images of the abdomen of dogs positioned in ventral recumbency on a gamma camera. Images were acquired 2 hours after IV injection of 99mTC-MIBI to an MDR1 WT/WT dog and to an MDR1 mut/mut dog Intense uptake of 99mTC-MIBI in the gallbladder (arrowhead) is present in MDR1 normal dog. A void of activity in the location of the gallbladder (arrow) is present in MDR1 mutant dog Gallbladder is almost empty and the substrate has surrounded the area.
41
In intact dogs, an intact P-gp: * limits drug ____ into the organism after ____ administration * promotes drug ______ into the ___ and \_\_\_\_ * restricts drug penetration across the \_\_\_\_\_-\_\_\_\_ barrier
entry, oral, elimination, bile, urine, blood-brain
42
In MDR1(-/-) dogs, a defective P-gp leads to: * _________ drug absorption * _________ biliary and urinary elimination * _______ permeation of blood-tissue barriers (i.e., blood-brain, blood-testis, blood-placenta barriers)
↑ increased, ↓ reduced, ↑ increased
43
P-gp transported drugs can cause an _______ in adverse effects in MDR1(?) dogs, especially when treated with _______ \_\_\_\_\_\_ like ivermectin.
increase, -/-, macrocyclic lactones
44
Neurotoxicity to ivermectin in MDR1 defect is characterized by:
Depression, ataxia, somnolence, salivation, tremor, coma, death
45
Neurotoxicity to ivermectin in MDR1 defect
46
Depending on the ______ and the mechanism of \_\_\_\_, drugs that are MDR1 substrates can cause severe ________ leading to \_\_\_\_\_.
doses, action, depression, death
47
+/+ = normal, -/- = no protein present Size is different (see bp numbers on right). If heterozygous, will normally not show signs of toxicity; if give very high dose, will show signs of toxicity.
48
All breeds related to this defect.
49
Genotype +/+ = ?
wild type
50
Genotype +/- = ?
Heterozygous
51
Genotype -/- = ?
Homozygous mutated
52
Dogs, homozygous for this mutation (MDR1? ) are highly _______ to many MDR1-transported drugs
-/-, sensitive
53
Collie most susceptible Humans don't have this problem
54
Do we have to know this? No
55
The MDR1 defect has been detected in cats of the breeds ____ \_\_\_\_\_ which showed ______ toxicity after ivermectin application. Defect has also been detected in ?
Maine Coon, neurological, Siamese, Ragdolls, Turkish Angora.
56
MDR1 defect in cats Affected cats show a ________ \_\_\_-bp _____ in the MDR1 gene (MDR1 nt1930(del2)).
homozygous, 2, deletion
57
Both proteins are similar in length (1,200 AA) but in the mutated MDR1, the protein is longer than in the dog but still defective.
58
Cytochrome P450 (CYP) enzyme deficiencies Cytochrome are \_\_\_\_\_\_-containing proteins located in the membrane of the _______ \_\_\_\_\_.
heme, endoplasmic reticulum
59
CYPs catalyze phase _ \_\_\_\_\_\_\_\_\_\_ reactions (oxidation and reduction).
I biotransformation
60
CYP1A2 deficiency Single nucleotide polymorphisms (SNPs) → _____ mutation (C1117T) that produces a change in the ______ frame, a _______ stop codon, and as a result, a _______ protein (no \_\_\_\_\_-binding domain)
nonsense, reading, premature, shortened, heme
61
62
CYP1A2 deficiency Dogs homozygote of the mutant allele (\_\_/\_\_) are considered “poor \_\_\_\_\_\_\_\_." As a result, drugs become _____ concentrated in blood → \_\_\_\_\_\_. Affected breeds: ?
m/m, metabolizers, highly, toxicity, Beagle, Irish Wolfhound, Whippet, Dalmatian, Australian Shepherd
63
CYP1A2 substrate drugs: ? ## Footnote **Do not have to know**
clomipramine, lidocaine, naproxen, ondansetron, propranolol, verapamil
64
Reduced expression of CYP1A (Same as CYP1A2) in two affected dogs (poor metabolizing, PM-Beagles) Western Blot Presence of enzymes in EM1 and 2, no enzyme in PM1 and PM2.
65
Increased concentrations of the drug AC-3933 (radequinil, a cognitive enhancer) and its metabolites in normal dogs (A, enhanced metabolizers) and CYP1A (-/-) dogs (B, poor metabolizers) Healthy: Metabolite level reaches is not much higher than 1000. Unhealthy: Poor metabolizer dog and the level reaches 10,000
66
CYP2B11 deficiency is a _____ \_\_\_\_\_\_\_ _______ (SNPs) identified (mechanism not fully understood).
single nucleotide polymorphisms
67
Animals with a defective CYP2B11 show ?
an increased bioavailability and toxicity
68
Substrate drugs: ?
Propofol, ketoconazole, thiopental (extended recovery from anesthesia in affected dogs)
69
CYP2B11 deficiency Affected breeds: ?
Greyhound
70
CYP2D15 deficiency is a _____ \_\_\_\_\_\_ ______ (SNPs) cause changes in ______ activity
single nucleotide polymorphisms, enzymatic
71
Animals with a defective CYP2B11 show an ?
increased bioavailability and toxicity
72
CYP2D15 deficiency Substrate drugs: celecoxib, propranolol, dextromethorphan, imipramine Do not have to know
73
CYP2D15 deficiency Affected breeds: ?
Beagle
74
N-acetyltransferase genes (NAT1 and NAT2) Both N-acetyltransferase genes are _____ in dogs * Increase the risk for _______ reactions and adverse effects from drugs that are metabolized by N-acetyltransferase enzyme: \_\_\_\_\_\_\_, \_\_\_\_\_\_\_, ____ and other drugs * Cats lack NAT\_\_ but express NAT\_\_
absent, hypersensitivity, sulfonamides, procainamide, hydralazine, 2, 1
75
N-acetyltransferase genes (NAT1 and NAT2) * Increase the risk for __________ reactions and _____ effects from drugs that are metabolized by ___________ enzyme: sulfonamides, procainamide, hydralazine and other drugs * Cats lack NAT2 but express NAT1
hypersensitivity, adverse, N-acetyltransferase
76
N-acetyltransferase genes (NAT1 and NAT2) • Cats lack _____ but express NAT1
NAT2
77
Glucuronyl transferase deficiency Deletion on the __________ \_\_\_\_\_\_\_\_\_ transferase gene (UGT1A6 gene) leads to an extremely reduced ____________ capacity → accumulation of the drug and _____ \_\_\_ effects. The accumulating drug will be then via the alternative metabolic pathway using _________ \_\_\_\_ detoxified Affected species/breeds: ?
uridinephosphate glucuronydil, glucuronydation, toxic adverse, cytochrome P450, Cats/all breeds, lions, civet cats
78
If cat is intoxicated with paracitomal This produces the metabolite ________________ (?) which is a harmful metabolite.
N-acetyl-p-benzo-quinon-imin (NAPQI)
79
NAPQI is detoxified using ______ (\_\_\_). Due to the ____ GSH reserves in cats, NAPQI accumulates causing _____ \_\_\_\_\_\_ and __________ formation (\_\_\_\_\_\_ \_\_\_\_\_) in the red blood cells. Substrate drugs: p-aminophenol derivatives such as phenacetine, paracetamol, phenylbutazone
glutathione, GSH, low, liver necrosis, methemoglobin, Heinz bodies
80
Heinz bodies